Treatment of Chronic Anemia With Epoetin Alfa in Elderly
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00337441|
Recruitment Status : Unknown
Verified June 2006 by Research and Education Foundation of Michael Reese Hospital.
Recruitment status was: Active, not recruiting
First Posted : June 16, 2006
Last Update Posted : June 16, 2006
|Condition or disease||Intervention/treatment||Phase|
|Anemia||Drug: Epoetin Alfa (drug)||Phase 2|
Chronic Anemia is common among elderly. Given their somewhat non-specific nature, the clinical symptoms of anemia are often difficult to attribute directly to the anemia itself. However, it is known that anemic older adults are at an increased risk of mortality, disability, higher risk of falls, poorer quality of life, worsening cognitive function, increase hospitalization risk, and increased healthcare utilization than their non-anemic counterparts.
Yet so far, there have been no treatment studies to demonstrate the benefits of correction of chronic anemia.
Epoetin Alfa (Procrit) is a manufactured form of a naturally occurring hormone that is given as an injection by a medical professional to stimulate the bone marrow's production of red blood cells.
This study is to explore, can chronic anemia be corrected with epoetin alfa and does the subsequent correction lead to an improvement in fatigue, quality of life or mobility among elderly.
Overall this is a 32 week treatment study.
In this study, participants with chronic anemia will receive either Epoetin alfa or placebo (saline injection) under the skin for 16 weeks. After 16 weeks the participants who were receiving epoetin will be switched to placebo and those who were receiving placebo earlier will go on now to receive epoetin alfa for 16 weeks.
At the end of 32 weeks we will compare, if epoetin alfa corrected the anemia, how individuals felt in respect to their fatigue levels, quality of life and did mobility improve during the study.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||62 participants|
|Intervention Model:||Crossover Assignment|
|Official Title:||Chronic Anemia And Fatigue In Elderly Patients: A Randomized Double-Blind Placebo-Controlled Cross-Over Study With Epoetin Alfa.|
|Study Start Date :||January 2003|
|Estimated Study Completion Date :||July 2005|
- Quality of Life
- Quality of Life
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00337441
|United States, Illinois|
|John H. Stroger Jr. Hospital of Cook County|
|Chicago, Illinois, United States, 60612|
|Mercy Hospital and Medical Center|
|Chicago, Illinois, United States, 60616-2477|
|Principal Investigator:||Parag Agnihotri||Research and Education Foundation of Michael Reese|